AGN : Summary for Allergan plc Ordinary Shares - Yahoo Finance

U.S. Markets closed

Allergan plc (AGN)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
189.73-1.21 (-0.63%)
At close: 4:02 PM EST

189.20 -0.53 (-0.28%)
After hours: 4:21 PM EST

People also watch:
BIIBCELGVRXGILDREGN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close190.94
Open187.91
Bid186.60 x 100
Ask189.42 x 100
Day's Range184.75 - 190.51
52 Week Range184.50 - 317.48
Volume6,857,637
Avg. Volume4,712,971
Market Cap71.16B
Beta1.09
PE Ratio (TTM)5.32
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.80 (1.48%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Biotech analyst: Republicans will protect drug companies from Trump
    Business Insider3 hours ago

    Biotech analyst: Republicans will protect drug companies from Trump

    Drugmaker shares were reeling on Wednesday after president elect Donald Trump addressed drug...

  • Teva Pharmaceutical Industries Ltd (ADR) (TEVA)’s End-Of-Year Switch Of Generics CEO Surprises Investors
    Insider Monkey3 hours ago

    Teva Pharmaceutical Industries Ltd (ADR) (TEVA)’s End-Of-Year Switch Of Generics CEO Surprises Investors

    Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shareholders were treated to an unpleasant surprise by generics CEO Siggi Olafsson, who is said to be jumping ship. The move has also scared off investors and sent Teva shares south. But apparently, analysts were not puzzled by the news that Olafsson was turning the reins over to Dipankar […]

  • Barrons.com5 hours ago

    Don't Expect Allergan To Rebound In 2017

    Piper Jaffray’s David Amsellem and his team take a look at Allergan (AGN) Wednesday, and they aren’t optimistic about the stock’s prospects in 2017. Amesellem writes that data from retail prescription volumes across Allergan’sU.S. commercial portfolio reinforced their concerns about Allergan’s business. As such, he writes that he doesn’t think Allergan is poised for a rebound, and the shares valuation reflect the Street’s overly rosy growth expectations.